Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Phase 2RecruitingNCT06824454

Stanford University90 enrolled

Overview

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypophosphatemia Kidney Transplantation

Interventions

Dipyridamole 75 MGDRUG

Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult kidney transplant patients. * No known contraindications to Dipyridamole Exclusion Criteria: * Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Locations (1)

Stanford University

Stanford, California, United States

RECRUITING

Outcomes

Primary Outcomes

Change in Serum Phosphorus Levels After Dipyridamole Administration

This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.

Time frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.